nach oben

Erschienen in:

01.09.2021 | News item

FDA requires updated safety warnings for Janus kinase inhibitors

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

The US FDA is requiring new and updated safety warnings about an increased risk of major adverse cardiovascular events, cancer, thrombosis and mortality for the Janus kinase (JAK) inhibitors tofacitinib [Xeljianz, Xeljianx XR], baricitinib [Olumiant] and upadacitinib [Rinvoq]. …

FDA. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions Internet Document : 1 Sep 2021. Available from: URL: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death?utm_medium=email&utm_source=govdelivery

Titel: FDA requires updated safety warnings for Janus kinase inhibitors
Publikationsdatum: 01.09.2021
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-021-01928-z

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

FDA requires updated safety warnings for Janus kinase inhibitors

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Cotrimoxazole/sodium-valproate

Methotrexate

Blinatumomab

Pemigatinib

Ceftazidime/teicoplanin

Covid-19-vaccine-pfizer-biontech